Dianthus Therapeutics (NASDAQ:DNTH) Issues Quarterly Earnings Results

Dianthus Therapeutics (NASDAQ:DNTH) issued its quarterly earnings data on Wednesday. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.94) by $0.13, FiscalAI reports. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The business had revenue of $1.21 million during the quarter, compared to analyst estimates of $0.46 million.

Dianthus Therapeutics Stock Down 4.7%

Dianthus Therapeutics stock traded down $4.03 during trading hours on Thursday, hitting $81.78. The stock had a trading volume of 167,716 shares, compared to its average volume of 932,282. The stock has a market capitalization of $4.48 billion, a P/E ratio of -19.63 and a beta of 1.47. Dianthus Therapeutics has a 12-month low of $33.85 and a 12-month high of $117.88. The stock’s 50-day moving average price is $91.11 and its 200-day moving average price is $85.18.

Insider Activity

In other news, Director Anne McGeorge sold 7,750 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $109.01, for a total transaction of $844,827.50. Following the sale, the director owned 1,250 shares in the company, valued at $136,262.50. This represents a 86.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Simon Read sold 2,778 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $117.55, for a total value of $326,553.90. Following the sale, the director directly owned 2,778 shares in the company, valued at $326,553.90. This trade represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 242,429 shares of company stock valued at $26,118,913. Company insiders own 3.02% of the company’s stock.

Wall Street Analyst Weigh In

DNTH has been the topic of several research analyst reports. Raymond James Financial reiterated a “strong-buy” rating and set a $134.00 price target on shares of Dianthus Therapeutics in a research report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Thursday, October 15th. Roth Capital began coverage on Dianthus Therapeutics in a report on Tuesday, October 27th. They set a “buy” rating and a $113.00 target price on the stock. Truist Financial raised their target price on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Wedbush lifted their price target on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $128.77.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for autoimmune and inflammatory diseases. The company’s research centers on the complement system, an important part of the immune response that can contribute to tissue damage and disease when improperly activated.

Dianthus’ lead product candidate, DNTH103, is an investigational, fully human monoclonal antibody designed to selectively inhibit C1s, a key protein in the classical complement pathway.